Summit Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SMMT | 9966.HK | AVBP | 2616.HK | 688382.SS | GMAB | |
|---|---|---|---|---|---|---|
| Market cap | 12.90B | 6.43B | 665.16M | 8.98B | 8.38B | 33.89B |
| P/E (TTM) | — | — | — | — | — | 43.4 |
| Forward P/E | -13.8 | -21.0 | -3.6 | 137.0 | -43.8 | 34.9 |
| Price/book | 19.0 | 3.3 | 1.8 | 5.9 | 6.6 | 5.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −12.56% | −39.84% | −28.97% | −7.84% | −48.70% | +90.20% |
| Today | +2.34% | +1.68% | +3.61% | +4.16% | +4.33% | −0.72% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SMMT news ›Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on Monday
Posted by Mitch Edgeman on Nov 4th, 2026 Read Our Latest Stock Analysis on Summit Therapeutics Summit Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of…
Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial
Nature Medicine (2026) Cite this article Ivonescimab is a tetravalent bispecific antibody targeting PD-1 and VEGF. Based on the potential therapeutic synergy between anti-VEGF therapy and PD-1/PD-L1 blockade, we conducted this phase 2…
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology MIAMI & SEOUL, South Korea--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc.…
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
Dec 08, 2025, 21:02 ET Beyond the previously reported efficacy data presented at the ESMO 2025 Presidential Symposium and simultaneously published in The Lancet, this presentation further disclosed patient-reported quality of life outcomes…
Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Pfizer (PFE) and Summit Therapeutics (SMMT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD), Pfizer (PFE) and Summit Therapeutics (SMMT). In a report released today, Alec Stranahan from Bank of America Securities…
Oral IDH1 Inhibitor Ivosidenib Holds Rare Liver Cancer at Bay for 35 Months in Case Report
A case report documents 35 months of oral ivosidenib therapy with partial remission and no adverse events in a man with IDH1-mutant combined hepatocellular–cholangiocarcinoma after chemotherapy failure. News Source: Nathaniel Bowman.…
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together. ... Biotechnology & Medical Research AstraZeneca…
Dr Bridgewater Weighs Potential Sequencing After Ivonescimab and the Future of BTC Therapy
THE COUNTDOWN IS ON John Bridgewater, BA, MBBS, MRCP, PhD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced biliary tract cancer. The PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy improved…
Summit Therapeutics reports survival benefit for cancer drug in trial
Summit says ivonescimab beat Imfinzi in late-stage biliary tract cancer. See trial survival data, safety findings and why U.S. Summit Therapeutics (SMMT) on Sunday said its experimental cancer drug ivonescimab helped patients with advanced…
Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026
Summit Therapeutics Inc. noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific... noted that data from the Phase III…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com12
- stocktitan.net4
- markets.businessinsider.com3
- defenseworld.net1
- hoodline.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.